Marker Therapeutics (MRKR) Current Deferred Revenue (2021 - 2025)
Marker Therapeutics (MRKR) reported Current Deferred Revenue of $974799.0 for Q4 2025, down 30.37% quarter-over-quarter from $1.4 million in Q3 2025.
Marker Therapeutics (MRKR) Current Deferred Revenue (2021 - 2025) Analysis & Trends
Marker Therapeutics (MRKR) has 4 years of Current Deferred Revenue data on file, last reported at $974799.0 in Q4 2025.
- Current Deferred Revenue for Q4 2025 came in at $974799.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $974799.0 (changed N/A YoY), and the FY2025 annual result was $974799.0, changed N/A from the prior year.
- Current Deferred Revenue eased to $974799.0 in Q4 2025 per MRKR's latest filing, from $1.4 million in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $1.4 million in Q2 2025 and troughed at $107530.0 in Q3 2023.
- A 4-year average of $868396.5 and a median of $1.1 million in 2021 frame the typical range for Current Deferred Revenue.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Marker Therapeutics | 28.20 Mn | 28.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 974,799.00 |
| Sep 30, 2025 | 1.40 Mn |
| Jun 30, 2025 | 1.40 Mn |
| Sep 30, 2023 | 107,530.00 |
| Mar 31, 2022 | 181,864.00 |
| Dec 31, 2021 | 1.15 Mn |